<DOC>
	<DOCNO>NCT00314925</DOCNO>
	<brief_summary>The primary purpose study determine Seneca Valley Virus may administer safely patient certain type advance cancer .</brief_summary>
	<brief_title>Safety Study Seneca Valley Virus Patients With Solid Tumors With Neuroendocrine Features</brief_title>
	<detailed_description>This first study man Seneca Valley Virus , virus seek kill certain tumor non-human model system . Subjects trial patient advance cancer display certain specified neuroendocrine feature , pathologically ; exhaust standard method treatment tumor . The primary purpose trial determine virus may administer safely . Additional purpose learn distribution virus body , elimination virus body , immune response virus whether virus might beneficial effect upon tumor patient . The first patient treat low amount virus subsequent patient may receive high amount . At end trial , intend select dose study .</detailed_description>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>Patients must histologically confirm solid tumor ( include carcinoid ) neuroendocrine feature ( i.e. , expression &gt; = 1 follow 3 marker : synaptophysin , chromogranin A , CD56 ) metastatic unresectable standard curative palliative measure exist longer effective . Patients must show evidence disease progression three month prior treatment SVV001 . Age &gt; = 18 year . Because dose adverse event data currently available use SVV001 patient &lt; 18 year age , child exclude study . Children may eligible future pediatric Phase I singleagent trial . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy &gt; = 24 week . Adequate bone marrow , hepatic , renal function define : absolute lymphocyte count &gt; = 1,000/ul absolute neutrophil count &gt; = 1,500/ul platelet &gt; = 100,000/ul AST/ALT &lt; = 2.5 x upper limit normal ( ULN ) &lt; = 5 x ULN liver metastases present total bilirubin &lt; = 1.5 x upper limit normal creatinine &lt; = 1.5 x upper limit normal OR creatinine clearance ( calculate ) &lt; = 60 mL/min/1.73 m2 patient creatinine &gt; 1.5 x upper limit normal . Women must surgically sterilize postmenopausal . Men must agree use adequate contraception ( barrier method birth control ; abstinence ) prior study entry 6 month . Ability understand willingness sign write informed consent document . Patients must oxygen saturation least 95 % room air . Patients must measurable disease RECIST ( CT and/or MRI ) . Patients small cell histology . Patients hospitalized emergent condition require inpatient evaluation , treatment procedure 30 day prior entry study . In addition , emergent condition require inpatient evaluation , treatment procedure must resolve medically stable severe 30 day prior entry study . Use chemotherapy radiotherapy within 4 week initiation SVV001 , continue &gt; Grade 1 adverse event , exclude alopecia , due agent administer 4 week earlier . Patients clinically evident Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) infection . Patients &gt; Grade 1 peripheral neuropathy ( CTCAE version 3.0 ) . Concurrent use investigational agent . Presence history central nervous system metastasis . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Premenopausal woman surgically sterilize . Although SVV001 affect ovary toxicological perspective , SVV001 RNA present ovary 12 week animal administer high medium dos . No preclinical reproductive test conduct SVV001 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>advanced carcinoma</keyword>
	<keyword>carcinoid</keyword>
	<keyword>neuroendocrine feature</keyword>
	<keyword>oncolytic virus</keyword>
	<keyword>phase I study</keyword>
	<keyword>dose escalation study</keyword>
	<keyword>rhabdomyosarcoma</keyword>
	<keyword>alveolar rhabdomyosarcoma</keyword>
	<keyword>medulloblastoma</keyword>
	<keyword>rhabdoid</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>ewing 's sarcoma</keyword>
	<keyword>pediatric oncology</keyword>
	<keyword>neuroblastoma</keyword>
	<keyword>wilms ' tumor</keyword>
	<keyword>retinoblastoma</keyword>
	<keyword>Large cell lung cancer</keyword>
</DOC>